Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 5, 2015, Pages 580-585

  Kierkuś, Jarosław ^a   Iwańczak, Barbara ^b   Grzybowska Chlebowczyk, Urszula ^c   Łazowska, Izabella ^d   Maślana, Jolanta ^e   Toporowska Kowalska, Ewa ^f   Czaja Bulsa, Grazyna ^f   Mierzwa, Grazyna ^g   Korczowski, Bartosz ^h   Czkwianianc, Elzbieta ^f   Zabka, Alicja ^f   Szymańska, Edyta ^a   Krzesiek, Elzbieta ^b   Więcek, Sabina ^c   Sładek, Małgorzata ⁱ  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e Wl Buszkowski Kielce Province Children s Hospital   (Poland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g POMERANIAN MEDICAL UNIVERSITY   (Poland)

^h NICOLAUS COPERNICUS UNIVERSITY   (Poland)

ⁱ JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Children; Crohn disease; Infliximab

Indexed keywords

AZATHIOPRINE; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE;

ADOLESCENT; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DRUG COMBINATION; FEMALE; HUMAN; MAINTENANCE CHEMOTHERAPY; MALE; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; AZATHIOPRINE; CHILD; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 85027955112     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000684     Document Type: Article

References (33)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369: 1641–57.
2. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334:841–8.
3. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423–39.
4. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28–62.
5. Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2006;12:1093–100.
6. Cucchiara S, Morley-Fletcher A. ‘‘New drugs: kids come first": children should be included in trials of new biological treatments. Inflamm Bowel Dis 2007;13:1165–9.
7. Rosenbach Y, Hartman C, Shapiro R, et al. Adalimumab treatment in children with refractory Crohn’s disease. Dig Dis Sci 2010;55:747–53.
8. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis 2009;15:816–22.
9. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77:847–69.
10. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863–73.
11. Ruemmele FM, Lachaux A, Cézard JP, et al. Efficacy of infliximab in pediatric Crohn’s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009;15:388–94.
12. Cottone M, Renna S, Orlando A, et al. Medical management of Crohn’s disease. Expert Opin Pharmacother 2011;12:2505–25.
13. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644–59.
14. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology 2004;126:1257–69.
15. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362:1383–95.
16. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199–212.
17. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054–61.
18. Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease. Eur J Gastroenterol Hepatol 2011;23:1100–10.
19. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.
20. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36–41.
21. Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134:1861–8.
22. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–47.
23. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–12.
24. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52–65.
25. Feagan B, MacDonald JWD, Panaccione R. A randomized, placebo-controlled study to evaluate the efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn’s disease. Gastroenterology 2008;134:682.
26. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228–38.
27. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829–38.
28. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009;136: 441–50.
29. El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn’s fistulas. Colorectal Dis 2012;14:1217–23.
30. Kierkus J, Dadalski M, Szymanska E, et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn’s disease. Eur J Gastroenterol Hepatol 2012;24:495–500.
31. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–36.
32. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265–7.
33. Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;57:1639–41.